Despite beating analyst expectations in second-quarter earnings with $3.68 billion revenue and significant earnings per share growth, Regeneron dealt with regulatory challenges. The FDA issued a complete response letter for odronextamab, their bispecific antibody for follicular lymphoma, attributing delays to manufacturing problems at a Catalent facility acquired by Novo Nordisk. Additionally, three high-dose Eylea applications faced postponements linked to the same manufacturing site issues. Regeneron's leadership remains optimistic about eventual approval once manufacturing challenges are resolved.